Signal Note — Healthcare PE

The Healthcare Squeeze

Three Fronts. One Margin War. The $200B CDMO Wave as the Investable Signal.

Healthcare PE | Reimbursement | Regulatory Enforcement | Human-Intel-Driven  ·  February 2026

PE healthcare portfolios are absorbing three independent margin compressions simultaneously — pharma MFN tariff bifurcation, Medicare Advantage rate collapse (0.09% proposed increase versus 5–7% cost inflation), and price transparency enforcement that is exposing the hidden markup infrastructure that underwrites hospital-affiliated services. The confluence is not cyclical. It's structural. And the $200 billion CDMO investment wave is the investable signal hiding inside the noise.

The Three-Front Margin War

Front 1: Pharma MFN Tariff Bifurcation. The administration's Most Favored Nation drug pricing executive order creates a structural bifurcation: manufacturers who comply face direct margin compression; those who resist face regulatory pressure. PE-backed specialty pharma and distributor portfolios that assumed price stability in their underwriting models are carrying unmodeled exposure in both directions.

Front 2: MA Rate Collapse. CMS proposed a 0.09% increase for 2027 rates — against industry-modeled 5–7% cost inflation. The gap is not a negotiating position. It reflects a bipartisan political alignment around MA overpayment that crystallized with the JEC report quantifying the cost to voters. Portfolios modeled on 4–6% annual rate increases face a structural repricing.

Front 3: Price Opacity Enforcement. Hospital price transparency rules are generating the data that enables both private litigation and CMS enforcement against inflated facility fees, surprise billing through out-of-network referral networks, and the markup infrastructure that hospital systems have used to cross-subsidize PE-backed physician group acquisitions.

Three independent regulatory vectors closing simultaneously on the same underlying margin pool. The healthcare PE model was built on regulatory arbitrage — and the arbitrage is closing.

The CDMO Signal

The investable secondary effect hiding inside the healthcare margin compression story: a $200 billion CDMO (contract development and manufacturing organization) investment wave is underway as pharmaceutical companies respond to MFN pressure, supply chain nationalism, and the need to diversify production away from Chinese and Indian generic manufacturers. The companies executing this build-out are mid-market, manufacturing-intensive, and PE-compatible.

Who's Exposed

  • MA-concentrated physician groups — the double hit is multiplicative: flat rates and chart review exclusion
  • Hospital-affiliated specialty practices built on facility fee cross-subsidization — price transparency enforcement is exposing the markup infrastructure
  • PE-backed specialty pharma distributors with MFN exposure in either direction

Who Wins

  • CDMO platforms — $200B investment wave driven by supply chain nationalism and MFN compliance pressure
  • Value-based care models with payor diversification — not concentrated in MA
  • PE sponsors who can disaggregate regulatory arbitrage margin from genuine operational margin in diligence
The strongest counter: PE healthcare has survived previous reimbursement pressure through lobbying, phase-in timelines, and congressional relief. True — but the simultaneous closure of three independent channels, each with bipartisan political support, is structurally different from any single regulatory action in the last decade.

Healthcare Portfolio Margin Decomposition

SGA can identify which margin components in specific PE healthcare portfolio companies are regulatory-arbitrage-dependent versus operationally durable — and model the impact of three simultaneous compression vectors on coverage ratios and exit valuations.

satish@sarrattglobal.com

Connected Signals